Monday 30 January 2012

Hocine Sidi-Said has contributed a lot to the pharmaceutical industry for a period of over 20 years. He served the pharmaceutical giant Pfizer for about 17 years in Asia and Central and Eastern Europe. In India, Denmark and Indonesia, he held the position of the Managing Director for Pfizer.

In India, Hocine Sidi Said managed over 2800 employees of the $200Mn company, during which he also handled a 3 way legal merger of his company Pfizer, Parke-Davis and Pharmacia India Ltd. While he was in Indonesia, Hocine Sidi-Said brought his company from the 12th position to the 3rd position. He was recognized and appreciated by the Pfizer Corporate Finance team when he efficiently handled the Asian Crises. Hocine Sidi-Said was also involved in a successful alliance with Dexa-medica (a local company).

Hocine Sidi-Said later joined the UCB S.A as the Emerging Markets President in March 2005 and served there for over three years. During his tenure, the UCB SA doubled their revenues. He was the in charge for Latin America, Middle East and Asia Pacific, Africa divisions. He restructured Black Economic Empowerment (BEE) transaction in South Africa. He is also known for his work in the incorporation of the Schwarz industry in China, Philippines, Korea and Algeria.

Hocine Sidi Said’s contributions to several charitable initiatives were appreciated for their persistent focus on target communities and the usefulness of the programs. Major initiatives included the Naee Nigah Program, The Arpana Research, Cansupport, Charities Trust and many more.

Later Hocine Sidi-Said joined Moksha8 Inc, a bio-pharmaceutical company as an Executive Vice-President, where he focused mainly on eight territories viz. Brazil, Russia, India, China, Mexico, Turkey, Korea and MENA.

Currently he is serving as founder director of Bio-nAbler and additional director and board member for Glenmark Pharmaceuticals.

Hocine Sidi-Said’s extensive involvement in international businesses over 20 years has given him a decent standing in the international business scenario.